Dankner R, Boker L Keinan, Boffetta P, Balicer R D, Murad H, Berlin A, Olmer L, Agai N, Freedman L S
Unit for Cardiovascular Epidemiology, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel; Patient Oriented Research, The Feinstein Institute for Medical Research, Manhasset, North Shore, New York, United States.
The Israel Center for Disease Control, Israel Ministry of Health, Israel; School of Public Health, Faculty of Social Welfare and Health Sciences, Haifa University, Haifa, Israel.
Cancer Epidemiol. 2018 Dec;57:104-109. doi: 10.1016/j.canep.2018.10.010. Epub 2018 Oct 28.
This population-based historical cohort study examined whether poor glycemic-control (i.e., high glucose and HbA1c blood levels) in patients with diabetes is associated with cancer-risk.
From a large healthcare database, patients aged 21-89 years, diagnosed with diabetes before January 2002 (prevalent) or during 2002-2010 (incident), were followed for cancer during 2004-2012 (excluding cancers diagnosed within the first 2 years since diabetes diagnosis). Risks of selected cancers (all-sites, colon, breast, lung, prostate, pancreas and liver) were estimated according to glycemic-control in a Cox regression model with time-dependent covariates, adjusted for age, sex, ethnic origin, socioeconomic status, smoking and parity. Missing glucose or HbA1c values were imputed.
Among 440,000 patients included in our analysis, cancer was detected more than 2 years after diabetes diagnosis in 26,887 patients (6%) during the follow-up period. Associations of poor glycemic-control with all-sites cancer and most specific cancers were either null or only weak (hazard ratios (HRs) for a 1% HbA1c or a 30 mg/dl glucose increase between 0.94 and 1.09). Exceptions were pancreatic cancer, for which there was a strong positive association (HRs: 1.26-1.51), and prostate cancer, for which there was a moderate negative association (HRs: 0.85-0.96).
Overall, poor glycemic-control appears to be only weakly associated with cancer-risk, if at all. A substantial part of the positive association with pancreatic cancer is attributable to reverse causation, with the cancer causing poorer glycemic-control prior to its diagnosis. The negative association with prostate cancer may be related to lower PSA levels in those with poor control.
这项基于人群的历史性队列研究旨在探究糖尿病患者血糖控制不佳(即血糖和糖化血红蛋白水平升高)是否与癌症风险相关。
从一个大型医疗数据库中选取2002年1月之前(患病)或2002年至2010年期间(新发)诊断为糖尿病的21至89岁患者,在2004年至2012年期间对其进行癌症随访(不包括糖尿病诊断后前两年内诊断出的癌症)。在一个具有时间依存性协变量的Cox回归模型中,根据血糖控制情况估算选定癌症(所有部位、结肠、乳腺、肺、前列腺、胰腺和肝脏)的风险,并对年龄、性别、种族、社会经济地位、吸烟和生育情况进行调整。对缺失的血糖或糖化血红蛋白值进行插补。
在纳入我们分析的440,000名患者中,随访期间有26,887名患者(6%)在糖尿病诊断超过2年后被检测出患有癌症。血糖控制不佳与所有部位癌症及大多数特定癌症之间的关联要么不存在,要么很微弱(糖化血红蛋白每增加1%或血糖每增加30mg/dl的风险比在0.94至1.09之间)。例外情况是胰腺癌,其存在强正相关(风险比:1.26 - 1.51),以及前列腺癌,其存在中度负相关(风险比:0.85 - 0.96)。
总体而言,血糖控制不佳似乎与癌症风险的关联很弱,即便存在关联。与胰腺癌的正相关很大程度上可归因于反向因果关系,即癌症在诊断前导致血糖控制更差。与前列腺癌的负相关可能与控制不佳者较低的前列腺特异抗原水平有关。